Mizuho Reiterates Buy Rating on Biogen Inc. (BIIB)
Mizuho keeps its buy rating on Biogen Inc., setting a $221 price target, a 12.42% upside from the current price.
Key Points
- On June 15, 2026, Mizuho reiterated its buy rating for Biogen Inc., setting a price target of $221.
- Mizuho's $221 price target implies 12.42% upside from Biogen Inc.'s ($BIIB) current $196.58 share price.
- Biogen Inc. trades at $200.05 with a market cap of $29.53 billion and a P/E ratio of 21.51.
- Insiders, including Menelas Pangalos, recently bought shares, while analysts like Needham upgraded Biogen to buy.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mizuho has reaffirmed its confidence in Biogen Inc. by maintaining a buy rating and setting a price target of $221. This update was made on June 15, 2026, by analyst Salim Syed. Shares of Biogen were trading at $200.05 around this time.
Other Institutional Activity in Biogen
Several institutional investors have also been active in Biogen. BlackRock, Inc. increased its holdings by 1,163,231 shares, bringing its total to 15,974,601 shares valued at approximately $2.93 billion. FMR LLC made a significant addition of 3,381,678 shares, resulting in a total of 12,807,541 shares worth about $2.35 billion. State Street Corp added 8,902 shares, ending with 7,167,922 shares valued at $1.31 billion.
Biogen Inc. Stock Down 10.0%
Shares of Biogen Inc. (NasdaqGS: BIIB) recently traded at $200.05. The company boasts a market capitalization of $29.53 billion and a P/E ratio of 21.51, with a forward P/E of 11.99. Its beta is quite low at 0.177, indicating less volatility compared to the broader market. The stock's 52-week range is between $121.05 and $205.97, with a 50-day moving average of $188.79 and a 200-day moving average of $173.46. Biogen maintains a strong financial position with a current ratio of 3.07 and a quick ratio of 2.03.
$BIIB price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Biogen reported revenue of approximately $9.94 billion, with a modest growth rate of 1.9%. The company's net margin stands at 13.81%, and it achieved a return on equity of 7.7%. The next earnings report is expected on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
Recent insider activity at Biogen includes several purchases on June 9, 2026. Notable transactions include Menelas Pangalos buying 2,370 shares, Eric Rowinsky purchasing 1,505 shares, and Stephen Sherwin also acquiring 1,505 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
In addition to Mizuho's reiteration, Needham upgraded Biogen to a buy on June 8, 2026, with a target price of $255. RBC Capital maintained its buy rating on May 27, 2026, with a target of $227. The consensus among 30 analysts is a buy, with an average target price of $220.13.
About Biogen Inc.
Biogen Inc., headquartered in Cambridge, Massachusetts, is a major player in the healthcare sector, specifically within the drug manufacturing industry. The company is known for discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Under the leadership of CEO Christopher A. Viehbacher, Biogen employs around 7,500 people and offers treatments for conditions like multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.
Bottom Line
Mizuho's reaffirmation of its buy rating for Biogen Inc. underscores the investment community's interest in the company's potential. While this rating reflects past analysis, investors often track such updates for insights into market sentiment and potential stock movements. As always, it's important to remember that these ratings are backward-looking and may not necessarily predict future performance.
Get Biogen Inc. alerts
New 13F filings, insider trades, and analyst moves on $BIIB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.